Does the media refer more to XNCR or FHTX?

In the previous week, Xencor had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Xencor and 2 mentions for Foghorn Therapeutics. Xencor's average media sentiment score of 0.50 beat Foghorn Therapeutics' score of -0.31 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PHAR or FHTX?

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.31 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or FHTX?

In the previous week, MeiraGTx had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for Foghorn Therapeutics. MeiraGTx's average media sentiment score of 0.87 beat Foghorn Therapeutics' score of -0.31 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BIOA or FHTX?

In the previous week, Foghorn Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.31 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ETON or FHTX?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 2 mentions for Foghorn Therapeutics. Eton Pharmaceuticals' average media sentiment score of -0.05 beat Foghorn Therapeutics' score of -0.31 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Foghorn Therapeutics (FHTX) Competitors

$4.08 -0.06 (-1.35%)

As of 10:19 AM Eastern

Compare

FHTX vs. XNCR, PHAR, MGTX, BIOA, and ETON

Should you buy Foghorn Therapeutics stock or one of its competitors? MarketBeat compares Foghorn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Foghorn Therapeutics include Xencor (XNCR), Pharming Group (PHAR), MeiraGTx (MGTX), BioAge Labs (BIOA), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Foghorn Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Foghorn Therapeutics has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.56	-$91.92M	-$2.29	N/A
Foghorn Therapeutics	$28.22M	8.50	-$74.28M	-$1.16	N/A

In the previous week, Xencor had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Xencor and 2 mentions for Foghorn Therapeutics. Xencor's average media sentiment score of 0.50 beat Foghorn Therapeutics' score of -0.31 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

61.5% of Foghorn Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xencor has a net margin of -177.10% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Xencor presently has a consensus price target of $24.50, suggesting a potential upside of 68.90%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 179.84%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats Xencor on 10 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.31 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group presently has a consensus target price of $38.33, suggesting a potential upside of 190.84%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 179.84%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Pharming Group has a net margin of 3.30% compared to Foghorn Therapeutics' net margin of -266.88%. Pharming Group's return on equity of 4.64% beat Foghorn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Pharming Group has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.52	$2.85M	$0.16	82.38
Foghorn Therapeutics	$28.22M	8.50	-$74.28M	-$1.16	N/A

Summary

Pharming Group beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

MeiraGTx currently has a consensus price target of $25.83, suggesting a potential upside of 115.22%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 179.84%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market.

MeiraGTx has a net margin of -151.12% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Foghorn Therapeutics has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	13.66	-$114.20M	-$1.48	N/A
Foghorn Therapeutics	$28.22M	8.50	-$74.28M	-$1.16	N/A

In the previous week, MeiraGTx had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for Foghorn Therapeutics. MeiraGTx's average media sentiment score of 0.87 beat Foghorn Therapeutics' score of -0.31 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Foghorn Therapeutics beats MeiraGTx on 10 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Foghorn Therapeutics has a net margin of -266.88% compared to BioAge Labs' net margin of -871.75%. Foghorn Therapeutics' return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.31 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.5% of Foghorn Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioAge Labs presently has a consensus target price of $43.50, indicating a potential upside of 97.47%. Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 179.84%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Foghorn Therapeutics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	108.92	-$80.61M	-$2.40	N/A
Foghorn Therapeutics	$28.22M	8.50	-$74.28M	-$1.16	N/A

Summary

Foghorn Therapeutics beats BioAge Labs on 12 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Eton Pharmaceuticals has higher revenue and earnings than Foghorn Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.57	-$4.60M	-$0.07	N/A
Foghorn Therapeutics	$28.22M	8.50	-$74.28M	-$1.16	N/A

Eton Pharmaceuticals currently has a consensus price target of $41.00, indicating a potential upside of 21.39%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 179.84%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Eton Pharmaceuticals has a net margin of -1.70% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 2 mentions for Foghorn Therapeutics. Eton Pharmaceuticals' average media sentiment score of -0.05 beat Foghorn Therapeutics' score of -0.31 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market.

Summary

Eton Pharmaceuticals beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$239.55M	$3.52B	$6.58B	$12.14B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.52	20.35	24.81	24.06
Price / Sales	8.50	331.06	552.47	123.81
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-2.13	8.36	10.77	6.51
Net Income	-$74.28M	$23.85M	$3.56B	$337.03M
7 Day Performance	0.84%	4.10%	1.97%	0.10%
1 Month Performance	-3.22%	3.45%	1.45%	1.07%
1 Year Performance	-16.14%	57.16%	31.07%	28.66%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	2.4032 of 5 stars	$4.08 -1.4%	$11.43 +179.8%	-15.3%	$239.55M	$28.22M	N/A	120	Analyst Downgrade Gap Up
XNCR Xencor	1.7207 of 5 stars	$12.20 -0.1%	$24.50 +100.8%	+67.4%	$905.27M	$125.58M	N/A	280	Positive News
PHAR Pharming Group	3.0492 of 5 stars	$12.51 -2.3%	$38.33 +206.4%	+22.7%	$905.06M	$376.13M	80.09	280	Positive News
MGTX MeiraGTx	3.3421 of 5 stars	$9.71 -0.4%	$25.83 +166.0%	+87.2%	$902.94M	$81.39M	N/A	300
BIOA BioAge Labs	2.4663 of 5 stars	$20.49 +3.3%	$43.50 +112.3%	N/A	$881.94M	$8.99M	N/A	N/A	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. XNCR, PHAR, MGTX, BIOA, and ETON

How does Foghorn Therapeutics compare to Xencor?

Summary

How does Foghorn Therapeutics compare to Pharming Group?

Summary

How does Foghorn Therapeutics compare to MeiraGTx?

Summary

How does Foghorn Therapeutics compare to BioAge Labs?

Summary

How does Foghorn Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. XNCR, PHAR, MGTX, BIOA, and ETON

How does Foghorn Therapeutics compare to Xencor?

Which has stronger valuation & earnings, XNCR or FHTX?

Does the media refer more to XNCR or FHTX?

Which has more risk & volatility, XNCR or FHTX?

Do institutionals & insiders hold more shares of XNCR or FHTX?

Is XNCR or FHTX more profitable?

Do analysts rate XNCR or FHTX?

Summary

How does Foghorn Therapeutics compare to Pharming Group?

Do insiders & institutionals hold more shares of PHAR or FHTX?

Which has more volatility and risk, PHAR or FHTX?

Does the media favor PHAR or FHTX?

Do analysts recommend PHAR or FHTX?

Is PHAR or FHTX more profitable?

Which has stronger earnings & valuation, PHAR or FHTX?

Summary

How does Foghorn Therapeutics compare to MeiraGTx?

Do analysts prefer MGTX or FHTX?

Which has more volatility & risk, MGTX or FHTX?

Is MGTX or FHTX more profitable?

Which has preferable earnings & valuation, MGTX or FHTX?

Does the media favor MGTX or FHTX?

Do institutionals & insiders have more ownership in MGTX or FHTX?

Summary

How does Foghorn Therapeutics compare to BioAge Labs?

Is BIOA or FHTX more profitable?

Which has more volatility and risk, BIOA or FHTX?

Does the media prefer BIOA or FHTX?

Do institutionals & insiders believe in BIOA or FHTX?

Do analysts recommend BIOA or FHTX?

Which has better earnings and valuation, BIOA or FHTX?

Summary

How does Foghorn Therapeutics compare to Eton Pharmaceuticals?

Which has stronger valuation and earnings, ETON or FHTX?

Do analysts rate ETON or FHTX?

Is ETON or FHTX more profitable?

Do insiders & institutionals hold more shares of ETON or FHTX?

Does the media prefer ETON or FHTX?

Which has more volatility & risk, ETON or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools